Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
2011

Comparing Dalteparin and Enoxaparin for Preventing Blood Clots After Hip Surgery

Sample size: 150 publication 10 minutes Evidence: moderate

Author Information

Author(s): Dranitsaris George, Jelincic Valentina, Choe Yoonhee

Primary Institution: Augmentium Pharma Consulting, Toronto, Canada and Eisai Inc., Woodcliff Lake, New Jersey, USA

Hypothesis

Is there a difference in safety and efficacy between dalteparin and enoxaparin for preventing venous thromboembolic events following total hip replacement surgery?

Conclusion

Dalteparin and enoxaparin are similarly effective and safe for preventing blood clots after hip surgery.

Supporting Evidence

  • Both dalteparin and enoxaparin reduced the risk of venous thromboembolic events by 50% compared to placebo.
  • There were no significant differences in major bleeding, heparin induced thrombocytopenia, or death between the two drugs.
  • The study included a total of nine placebo-controlled trials.
  • Statistical methods were used to indirectly compare the two drugs due to the lack of head-to-head trials.

Takeaway

This study looked at two medicines that help prevent blood clots after hip surgery and found they work about the same.

Methodology

A literature search was conducted for randomized trials evaluating dalteparin or enoxaparin prophylaxis in THR patients, followed by meta regression analysis.

Potential Biases

Potential biases associated with indirect comparisons and limited statistical power due to the number of trials.

Limitations

The analysis was indirect and not a true non-inferiority study, and some trials were not double-blinded.

Participant Demographics

Patients undergoing elective total hip replacement surgery, aged over 18.

Statistical Information

P-Value

p<0.001

Confidence Interval

(0.40 - 0.61)

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1477-9560-9-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication